Bay Area startup Minerva Surgical has just raised $25 million for its device that treats menorrhagia, or abnormally heavy menstrual bleeding in women, according to a regulatory filing.
Minerva is developing a device, called the Aurora Endometrial Ablation System, that treats women with exceptionally heavy periods. The ray gun, that is, ablation device, seals the cervical canal with a balloon and zaps the endometrial lining with an electrode array – ending a woman’s menstrual woes within four minutes, the company asserts. A demo is available on the site.
The Redwood City-based company is in the midst of a 153-patient clinical trial that began in 2012 and is projected to be complete in 2016. It has a primary completion date in November this year, however, so stay tuned. The trial – and ultimately the procedure – is meant for women who do not want to have any more children.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Minerva has steadily raised a significant amount of capital since its 2008 launch – including this latest round, it’s received about $80 million in equity funding, according to a slew of regulatory filings. Calls to the company to detail what the latest funding round’s for have yet to be returned, however.
Minerva CEO David Clapper has led a number of surgical device companies, including SurgRx – a startup that was acquired by Johnson & Johnson’s Ethicon Endo-Surgery in late 2008. Before that, Clapper worked in management at J&J for 16 years.